LED vs. laser for fibromyalgia is one of the first practical questions people ask when evaluating photobiomodulation: do you need an expensive clinical laser, or can an LED-based device produce the same results? The clinical trial data answers this more directly than most device comparisons in medicine. The largest photobiomodulation trial in fibromyalgia used a device that combined both laser and LED sources (Silva et al., 2018), and the whole-body trials that produced improvements lasting six months used LED-based delivery systems. The distinction between laser and LED is primarily a delivery characteristic, not a biological one: a photon at 660nm triggers the same cellular response whether it originates from a laser or an LED. The difference is in how efficiently the energy reaches the target tissue, which affects dosing and treatment time.
This article is part of our complete guide to Red and Infrared Light Therapy for Fibromyalgia.
Key Takeaways
- The largest trial used LED + laser combined: The Silva et al. 2018 RCT (n=160) used a multi-wavelength cluster with red LEDs (640nm), infrared LEDs (875nm), and a super-pulsed laser (905nm). Both photobiomodulation alone and photobiomodulation combined with exercise produced significant improvements over placebo, with the combined therapy group showing the strongest results across all outcomes.
- Mechanisms are wavelength-dependent, not device-dependent: The mitochondrial response to photobiomodulation depends on the wavelength and energy density of the light, not on whether it comes from a laser or LED source. Both device types activate the same cellular pathways at equivalent parameters. (For the full mechanism, see How Red Light Therapy Works for Fibromyalgia.)
- No direct head-to-head comparison exists: No trial has compared LED-only to laser-only delivery for fibromyalgia in the same study. The evidence that both device types work comes from separate trials using different protocols, populations, and outcome measures. The 2025 systematic review (Martín Pérez et al.) included studies using laser, LED, and combined devices across 17 studies and 857 participants, with positive outcomes found across device types.
Understanding the Question: Why Device Type Matters for Fibromyalgia
Fibromyalgia involves widespread pain across multiple body regions, along with fatigue, sleep disruption, and cognitive difficulties. When people with fibromyalgia evaluate photobiomodulation, device type surfaces early: does the clinical evidence require an expensive clinical laser, or do LED-based devices produce comparable outcomes? The answer affects which products are relevant, what treatment looks like at home versus in a clinic, and how closely a consumer device can replicate what the clinical trials tested. (For the biological mechanisms explaining how photobiomodulation works at the cellular level, see How Red Light Therapy Works for Fibromyalgia.)
Fibromyalgia patients are already navigating a complicated treatment landscape. Exercise helps but is difficult when fatigue and pain make movement punishing. Medications work for a fraction of patients and come with side effects that many cannot tolerate. So when someone with fibromyalgia asks whether they need an expensive clinical laser or whether an LED device can produce the same result, that is not a trivial question. It is a question about access. The answer from the trial data is more straightforward than I expected: both device types have produced significant clinical improvements, the mechanism does not depend on coherence, and the specifications that matter are wavelength and energy delivery, not the label on the light source.— Dr. William Carter, MD
What the Fibromyalgia Trials Actually Used
The fibromyalgia evidence base includes trials using laser devices, LED devices, and combined devices. What each major trial used provides the clearest picture of what the evidence supports.
Silva et al. (2018), n=160: The largest photobiomodulation trial in fibromyalgia. Multi-wavelength cluster combining 905nm super-pulsed laser, 640nm red LEDs, and 875nm infrared LEDs, delivered to 11 tender points at 39.3 J per site. Both photobiomodulation alone and photobiomodulation combined with exercise significantly outperformed placebo, with the combined group showing the strongest results across all outcomes.
Ribeiro et al. (2023), n=90: Photobiomodulation combined with static magnetic field (PBMT-sMF) using a similar multi-wavelength cluster approach. Patients, therapists, and assessors were all blinded. Tender point count and pain intensity both improved significantly over placebo (p<0.0001 for each).
Navarro-Ledesma et al. (2022, 2024), n=42: Whole-body photobiomodulation using an LED-based delivery system (660nm red and 850nm near-infrared). Triple-blinded. The 2024 follow-up tracked the same patient cohort from the 2022 trial and found quality of life improvements persisting at every assessment through six months, with self-efficacy and kinesiophobia sustained from two weeks post-treatment onward.
Ruaro et al. (2014): 670nm GaAlAs laser. Fibromyalgia impact improvement at p=0.0003.
Fitzmaurice et al. (2023): Whole-body photobiomodulation using LED-based delivery. All symptom domains improved, sustained at 24 weeks.
Kelini et al. (2025), n=52: High-intensity laser therapy (HILT) using a 1064nm Nd:YAG laser at 3kW peak power, combined with exercise versus exercise alone. All outcomes improved at p<0.001. HILT operates at a different wavelength and substantially higher power than the low-level laser and LED devices used in the other fibromyalgia trials, making it a distinct modality within the broader phototherapy evidence base.
The 2025 Martín Pérez systematic review explicitly noted that photobiomodulation was applied via low-level laser, infrared, or LED-based devices across the 17 included studies, and improvements were found across delivery methods. That consistency across device types is the reason the laser-vs-LED question has a clearer answer here than in most areas of photobiomodulation research. (For the full clinical evidence across all trials, see PBM for Fibromyalgia: Clinical Evidence.)
Why the Distinction Matters Less Than You Think
The biological mechanism of photobiomodulation operates through light absorption at specific wavelengths by a key enzyme (cytochrome c oxidase) in the mitochondria. This enzyme responds to wavelength and energy density. A photon at 660nm from a laser and a photon at 660nm from an LED trigger the same absorption event. The device label is irrelevant at the molecular level.
Where lasers and LEDs differ is in practical delivery characteristics. Lasers produce a focused, coherent beam that delivers high power density to a small area. LEDs produce broader, divergent light that covers more area at lower power density per point. For localized treatment of specific tender points, a focused laser beam delivers energy more efficiently to a defined target. For whole-body treatment, LED arrays that cover large body surface areas are the practical choice.
For fibromyalgia, where pain is widespread across multiple body regions, both approaches have demonstrated clinical efficacy. The localized trials (Silva, Ribeiro, Ruaro) delivered therapy to defined tender point locations. The whole-body trials (Navarro-Ledesma, Fitzmaurice) covered the entire body surface. The clinical outcomes from both delivery approaches reached significance across pain, function, and quality of life, and the whole-body LED trials added the longest follow-up data in the fibromyalgia photobiomodulation literature.
The Network Meta-Analysis Perspective
The Gikaro et al. (2023) network meta-analysis of 54 studies and 3,045 participants across electrophysical agents for fibromyalgia found low to moderate quality evidence that laser therapy ranked among the most effective electrophysical agents for fibromyalgia. Across a broad landscape of physical modalities (TENS, ultrasound, magnetic therapy, pulsed electromagnetic fields), photobiomodulation consistently ranked at or near the top. Efficacy tracked with wavelength, energy density, and tissue targeting accuracy. Device type was downstream of those parameters.
What Matters for Device Selection
For fibromyalgia patients evaluating devices, the specifications that determine clinical relevance are wavelength, power output, energy density, and treatment area.
The wavelength should fall within the ranges studied in the clinical trials: 630–670nm for red light and 808–905nm for near-infrared. The device needs to deliver sufficient energy density to reach clinically relevant thresholds, and treatment time has to be practical for the number of body sites that need coverage. Fibromyalgia involves widespread pain. Covering it takes energy.
The Silva et al. (2018) trial delivered 39.3 J per tender point site across 11 locations, for a total session energy exceeding 430 J. Replicating this energy delivery with a lower-powered device is mathematically possible but requires longer treatment times. "Mathematically possible" is doing some heavy lifting in that sentence. The math works, but treatment time matters differently when the person using the device lives with fatigue as a primary symptom, and pretending the arithmetic is what matters ignores who the patient actually is. A device that delivers adequate power across multiple wavelengths, covering the relevant body areas within a practical session, aligns best with what the clinical evidence demonstrates.
(For the biological mechanisms behind the different wavelengths, see Red Light Benefits for Fibromyalgia and Infrared Light Benefits for Fibromyalgia. For the safety profile across device types, see Photobiomodulation Safety for Fibromyalgia. For how red light therapy addresses pain conditions beyond fibromyalgia, see Red Light Therapy for Back Pain.)
Where the Evidence Stands
The fibromyalgia evidence base includes trials using laser devices, LED devices, and combined devices, with positive clinical outcomes across all three. The biological mechanism is wavelength-dependent, which means the laser-vs-LED distinction is primarily practical: how efficiently light energy reaches the target tissue, how much body surface the device covers, and how long treatment takes. Both localized and whole-body delivery methods have produced significant results, and the 2025 systematic review confirmed improvements across device types. For someone choosing a device, the specifications that matter are wavelength (630–670nm red, 808–905nm near-infrared), sufficient power output to deliver clinically relevant energy within a realistic treatment session, and coverage that matches fibromyalgia's widespread symptom geography.
